Stryker has secured FDA clearance for its Incompass total ankle system to treat patients whose ankle joints have been damaged by severe rheumatoid, post-traumatic or degenerative arthritis. The ...

Stryker (NYSE:SYK) recently received FDA clearance for its Incompass® Total Ankle System, a significant product innovation that highlights the company's commitment to advancing patient care. Over the ...

StrykerSYK saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 64 to 71. Please watch the video at Investors.com - Stock Market Exposure: How To Make ...

According to Benzinga Pro, Stryker's peer group average for short interest as a percentage of float is 5.30%, which means the ...

Stryker (NYSE:SYK) announced today that it received FDA 510(k) clearance for its Incompass total ankle system.

Stryker received FDA 510(k) clearance for its Incompass® Total Ankle System, intended for patients with severe ...

This was the stock's third consecutive day of gains.

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

This has positioned BSX as the second-largest player globally, largely due to the rapid adoption of pulsed field ablation ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.